Skip NavigationSkip to Content
Return Return to Search Results

Antibodies to SARS-CoV-2 in All of Us Research Program Participants, January 2-March 18, 2020

  1. Author:
    Althoff, Keri N
    Schlueter, David J
    Anton-Culver, Hoda
    Cherry, James
    Denny, Joshua C
    Thomsen, Isaac
    Karlson, Elizabeth W
    Havers, Fiona P
    Cicek, Mine S
    Thibodeau, Stephen N
    Pinto,Ligia
    Lowy, Douglas
    Malin, Bradley A
    Ohno-Machado, Lucila
    Williams, Carolyn
    Goldstein, David
    Kouame, Aymone
    Ramirez, Andrea
    Roman, Adrienne
    Sharpless, Norman E
    Gebo, Kelly A
    Schully, Sheri D

  2. Author Address

    Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD & Consultant to the All of Us Research Program, National Institutes of Health, Bethesda, MD., National Human Genome Research Institute, National Institutes of Health, Bethesda, MD., Department of Medicine, School of Medicine, University of California, Irvine, Irvine, CA., National Cancer Institute, National Institutes of Health, Bethesda, MD., Vanderbilt University Medical Center, Nashville, TN., Harvard Medical School, Brigham and Women 39;s Hospital, Boston, MA., Centers for Disease Control and Prevention, Atlanta, GA., Mayo Clinic, Rochester, MN., Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD., School of Medicine, University of California, San Diego, San Diego, CA., National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD., Columbia University Medical Center, New York, NY., Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.,
    1. Year: 2021
    2. Date: Jun 15
    3. Epub Date: 2021 06 15
  2. Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  4. Type of Article: Article
  1. Abstract:

    With limited SARS-CoV-2 testing capacity in the US at the start of the epidemic (January - March), testing was focused on symptomatic patients with a travel history throughout February, obscuring the picture of SARS-CoV-2 seeding and community transmission. We sought to identify individuals with SARS-CoV-2 antibodies in the early weeks of the US epidemic. All of Us study participants in all 50 US states provided blood specimens during study visits from January 2 to March 18, 2020. A participant was considered seropositive if they tested positive for SARS-CoV-2 immunoglobulin G (IgG) antibodies on the Abbott Architect SARS-CoV-2 IgG ELISA and the EUROIMMUN SARS-CoV-2 ELISA in a sequential testing algorithm. Sensitivity and specificity of the Abbott and EUROIMMUNE ELISAs and the net sensitivity and specificity of the sequential testing algorithm were estimated with 95% confidence intervals. The estimated sensitivity of Abbott and EUROIMMUN was 100% (107/107 [96.6%, 100%]) and 90.7% (97/107 [83.5%, 95.4%]), respectively. The estimated specificity of Abbott and EUROIMMUN was 99.5% (995/1,000 [98.8%, 99.8%]) and 99.7% (997/1,000 [99.1%, 99.9%), respectively. The net sensitivity and specificity of our sequential testing algorithm was 90.7% (97/107 [83.5%, 95.4%]) and 100.0% (1,000/1,000 [99.6%, 100%]), respectively. Of the 24,079 study participants with blood specimens from January 2 to March 18, 2020, 9 were seropositive, 7 of whom were seropositive prior to the first confirmed case in the states of Illinois, Massachusetts, Wisconsin, Pennsylvania, and Mississippi. Our findings indicate SARS-CoV-2 infections weeks prior to the first recognized cases in 5 US states. Published by Oxford University Press for the Infectious Diseases Society of America 2021.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1093/cid/ciab519
  3. PMID: 34128970
  4. PII : 6294073

Library Notes

  1. Fiscal Year: FY2020-2021
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel